KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Accumulated Expenses (2016 - 2025)

Sarepta Therapeutics has reported Other Accumulated Expenses over the past 16 years, most recently at $8.0 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 40.88% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $8.0 million, down 40.88%, while the annual FY2025 figure was $8.0 million, 40.88% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $8.0 million at Sarepta Therapeutics, down from $10.2 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $17.8 million in Q4 2023 and troughed at $3.9 million in Q1 2021.
  • A 5-year average of $11.1 million and a median of $10.1 million in 2025 define the central range for Other Accumulated Expenses.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 68.34% in 2021 and later surged 351.17% in 2022.
  • Year by year, Other Accumulated Expenses stood at $15.1 million in 2021, then plummeted by 64.69% to $5.3 million in 2022, then skyrocketed by 235.81% to $17.8 million in 2023, then decreased by 24.5% to $13.5 million in 2024, then tumbled by 40.88% to $8.0 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for SRPT at $8.0 million in Q4 2025, $10.2 million in Q3 2025, and $5.9 million in Q2 2025.